Distinguished in Hepatorenal Syndrome

Dr. Jasmohan S. Bajaj

Gastroenterology
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
Accepting New Patients
20 Years of Experience
Distinguished in Hepatorenal Syndrome
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jasmohan Bajaj is a Gastroenterologist in Richmond, Virginia. Dr. Bajaj has been practicing medicine for over 20 years and is rated as a Distinguished provider by MediFind in the treatment of Hepatorenal Syndrome. His top areas of expertise are Liver Failure, Spontaneous Bacterial Peritonitis, Ascites, Liver Transplant, and Vagotomy. Dr. Bajaj is currently accepting new patients.

His clinical research consists of co-authoring 433 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Hepatorenal Syndrome.

Specialties
Gastroenterology
Licenses
Internal Medicine in WI
Languages Spoken
English
Hindi
Punjabi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS

Locations

1250 E Marshall St, Internal Medicine, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Health IT Generated PROs to Improve Outcomes in Cirrhosis
Health IT Generated PROs to Improve Outcomes in Cirrhosis
Enrollment Status: Completed
Publish Date: September 17, 2025
Intervention Type: Other
Study Phase: Not Applicable
Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis
Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis
Enrollment Status: Completed
Publish Date: September 09, 2025
Fecal Microbiota Transplant in Veterans With Cirrhosis
Fecal Microbiota Transplant in Veterans With Cirrhosis
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Other, Drug
Study Drugs: Fecal Microbial Transplant Capsules, Fecal Microbial Transplant Enema
Study Phase: Phase 1/Phase 2
Characterization of Venous Ammonia Levels in Fasted and Fed State in Patients With Cirrhosis After Vegetarian, Vegan and Non-Vegetarian Meals
Characterization of Venous Ammonia Levels in Fasted and Fed State in Patients With Cirrhosis After Vegetarian, Vegan and Non-Vegetarian Meals
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase 2 Randomized, Dose-Titration, Open-Label Study Evaluating the Safety and Efficacy of BIV201 Compared to Standard of Care to Reduce Ascites and Complications in Cirrhotic Patients With Refractory Ascites
A Phase 2 Randomized, Dose-Titration, Open-Label Study Evaluating the Safety and Efficacy of BIV201 Compared to Standard of Care to Reduce Ascites and Complications in Cirrhotic Patients With Refractory Ascites
Enrollment Status: Terminated
Publish Date: May 08, 2024
Intervention Type: Drug
Study Drug: Terlipressin Diacetate
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Double-Blind Randomized Placebo-Controlled Trial of Rifamycin SV MXX in Minimal Hepatic Encephalopathy (RIVET Trial)
A Double-Blind Randomized Placebo-Controlled Trial of Rifamycin SV MXX in Minimal Hepatic Encephalopathy (RIVET Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Other, Drug
Study Drug: Rifamycin SV MMX
Study Phase: Phase 2
HEAL STUDY (Hepatic Encephalopathy and Albumin Study): A Double-Blind Randomized Controlled Trial Of Albumin In Hepatic Encephalopathy
HEAL STUDY (Hepatic Encephalopathy and Albumin Study): A Double-Blind Randomized Controlled Trial Of Albumin In Hepatic Encephalopathy
Enrollment Status: Completed
Publish Date: May 31, 2022
Intervention Type: Biological, Other
Study Phase: Phase 2
Modulation of Gut-Brain Axis Using Fecal Transplant Capsules in Cirrhosis
Modulation of Gut-Brain Axis Using Fecal Transplant Capsules in Cirrhosis
Enrollment Status: Completed
Publish Date: May 19, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1
Ramelteon for Treatment of Insomnia in Cirrhosis
Ramelteon for Treatment of Insomnia in Cirrhosis
Enrollment Status: Completed
Publish Date: March 29, 2021
Intervention Type: Drug
Study Phase: Phase 4
Fecal Microbial Transplant for Alcohol Misuse in Cirrhosis
Fecal Microbial Transplant for Alcohol Misuse in Cirrhosis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Biological, Other
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
Oral Gut Liver Axis in Cirrhosis
Oral Gut Liver Axis in Cirrhosis
Enrollment Status: Completed
Publish Date: April 04, 2018
Intervention Type: Procedure
Study Phase: Not Applicable
Mindfulness and Support Group to Improve Patient and Caregiver Burden in Cirrhosis
Mindfulness and Support Group to Improve Patient and Caregiver Burden in Cirrhosis
Enrollment Status: Completed
Publish Date: January 12, 2017
Intervention Type: Other
Study Phase: Not Applicable
View 13 Less Clinical Trials

433 Total Publications

Salivary microbiome and serum metabolomics add to clinical biomarkers to predict 6-month hospitalizations in a multicenter cirrhosis outpatient cohort.
Salivary microbiome and serum metabolomics add to clinical biomarkers to predict 6-month hospitalizations in a multicenter cirrhosis outpatient cohort.
Journal: Hepatology (Baltimore, Md.)
Published: May 19, 2025
Similar Doctors
Elite in Hepatorenal Syndrome
Dr. Arun J. Sanyal
Gastroenterology
Elite in Hepatorenal Syndrome
Dr. Arun J. Sanyal
Gastroenterology

Mcv Associated Physicians

1200 E Marshall St, 
Richmond, VA 
 (0.1 miles away)
804-828-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arun Sanyal is a Gastroenterologist in Richmond, Virginia. Dr. Sanyal is rated as an Elite provider by MediFind in the treatment of Hepatorenal Syndrome. His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Cirrhosis, Liver Transplant, and Endoscopy. Dr. Sanyal is currently accepting new patients.

Experienced in Hepatorenal Syndrome
Dr. Raseen Tariq
Gastroenterology | Hospital Medicine
Experienced in Hepatorenal Syndrome
Dr. Raseen Tariq
Gastroenterology | Hospital Medicine

Mcv Associated Physicians

1001 E Leigh St, 
Richmond, VA 
 (1.9 miles away)
804-828-7929
Languages Spoken:
English
See accepted insurances

Raseen Tariq is a Gastroenterologist and a Hospital Medicine provider in Richmond, Virginia. Dr. Tariq is rated as an Advanced provider by MediFind in the treatment of Hepatorenal Syndrome. Her top areas of expertise are Pseudomembranous Colitis, Viral Gastroenteritis, Colitis, Colonoscopy, and Endoscopy.

Experienced in Hepatorenal Syndrome
Dr. Binu John
Gastroenterology
Experienced in Hepatorenal Syndrome
Dr. Binu John
Gastroenterology
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
 (0.1 miles away)
804-828-4060
Languages Spoken:
English

Binu John is a Gastroenterologist in Richmond, Virginia. Dr. John is rated as a Distinguished provider by MediFind in the treatment of Hepatorenal Syndrome. His top areas of expertise are Cirrhosis, Liver Cancer, Primary Biliary Cholangitis, Liver Failure, and Liver Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bajaj's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile